Pathos
Pathos is a biotechnology company using AI to re-engineer drug development through its PathOS platform for precision medicine.
Secondary Market Price
How Pathos Measures Up
To help you manage your Pathos equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Pathos's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Pathos Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Pathos's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Pathos is a clinical-stage biotechnology company that uses artificial intelligence to re-engineer drug development, with a specific focus on precision medicine for oncology. The company operates on the belief that cancer is a collection of hundreds of rare diseases, best understood by their underlying biological pathways. It utilizes its PathOS platform, which is built on oncology and genomic data, to license or co-develop clinical-stage therapeutics. Pathos was founded in 2020 and is headquartered in Chicago, Illinois.
Looking forward, the company aims to accelerate the translation of real-world data into therapies by optimizing patient selection strategies to shorten the path to drug approval. While no specific new projects have been announced, the company has had notable financial developments. A recent funding round valued Pathos at $1.60 billion. Additionally, the company completed a Series D funding round, raising $365 million in June 2025.
- New Enterprise Associates
- Revolution
- Lightbank
- Builders VC
- AstraZeneca PLC
- Tempus
- Co-Founder, Eric Lefkofsky
- Co-Founder, Ryan Fukushima
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Pathos worth joining?
Deciding if a startup is the right fit involves assessing its growth potential and the value of its equity compensation. Tools like Prospect can help you make an informed decision by comparing the potential equity outcomes across different companies.
What should I do with my Pathos stock?
Managing private company stock involves complex decisions around when to exercise options, when to sell, and how to minimize your tax burden. A platform like Prospect provides personalized, data-driven strategies to help you optimize the value of your equity.
Can you sell Pathos stock?
As a private company, Pathos stock isn't publicly traded, but you can typically sell shares during specific liquidity events like tender offers or on secondary markets. Prospect offers tools to help you navigate these opportunities and determine which shares are most tax-optimal to sell.
How can I find the value of my Pathos stock?
Valuing private stock is challenging because it isn't traded on public markets and its price isn't readily available. To help you understand what your equity could be worth, Prospect uses predictive models trained on VC-grade data to forecast your shares' future value.
What is Pathos's equity worth?
The true worth of your equity depends on the company's future success and your personal financial situation, not just a single valuation number. Platforms like Prospect can project a range of potential outcomes for your holdings to give you a clearer picture of their value.
What is Pathos's stock ticker symbol?
Pathos does not have a stock ticker symbol because it is a private company that is not yet publicly traded. Ticker symbols are only assigned to companies when they list their shares on a public stock exchange, such as the NYSE or NASDAQ.
Can I buy or sell Pathos stock?
As an employee, you can typically "buy" stock by exercising your vested options, and you can sell shares during approved liquidity events like secondary sales or tender offers. Prospect offers customized strategies for both exercising and selling to help you maximize your post-tax returns.
What is the criteria to buy or invest in Pathos stock?
For employees, the ability to acquire stock is typically granted through equity compensation plans, allowing you to exercise vested options. For outside investors, opportunities to invest in a private company like Pathos are generally limited to accredited investors during formal fundraising rounds.
